178 related articles for article (PubMed ID: 32720232)
1. Lifetime antiretroviral exposure and neurocognitive impairment in HIV.
Amusan P; Power C; Gill MJ; Gomez D; Johnson E; Rubin LH; Fujiwara E
J Neurovirol; 2020 Oct; 26(5):743-753. PubMed ID: 32720232
[TBL] [Abstract][Full Text] [Related]
2. Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort.
Ciccullo A; Baldin G; Borghi V; Lagi F; Latini A; d'Ettorre G; Oreni L; Fusco P; Capetti A; Fabbiani M; Giacomelli A; Grimaldi A; Madeddu G; Sterrantino G; Mussini C; Di Giambenedetto S
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062367
[TBL] [Abstract][Full Text] [Related]
3. Changes in functional connectivity in people with HIV switching antiretroviral therapy.
Toniolo S; Cercignani M; Mora-Peris B; Underwood J; Alagaratnam J; Bozzali M; Boffito M; Nelson M; Winston A; Vera JH
J Neurovirol; 2020 Oct; 26(5):754-763. PubMed ID: 32500477
[TBL] [Abstract][Full Text] [Related]
4. Empiric neurocognitive performance profile discovery and interpretation in HIV infection.
Gomez D; Power C; Gill MJ; Koenig N; Vega R; Fujiwara E
J Neurovirol; 2019 Feb; 25(1):72-84. PubMed ID: 30519968
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of drug-drug interactions in the era of HIV integrase inhibitors: a retrospective clinical study.
Baecke C; Gyssens IC; Decoutere L; van der Hilst JCH; Messiaen P
Neth J Med; 2017 Jul; 75(6):235-240. PubMed ID: 28741582
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral therapy among people with HIV with comorbidities in the United States: a retrospective cohort study.
Buysman EK; Kumar P; McNiff K; Goswami S; Paudel M; Prajapati G; Tadese BK
Curr Med Res Opin; 2023 Nov; 39(11):1451-1462. PubMed ID: 37766585
[TBL] [Abstract][Full Text] [Related]
7. A review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugs.
De Benedetto I; Trunfio M; Guastamacchia G; Bonora S; Calcagno A
J Neurovirol; 2020 Oct; 26(5):642-651. PubMed ID: 32737860
[TBL] [Abstract][Full Text] [Related]
8. Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.
Bourgi K; Rebeiro PF; Turner M; Castilho JL; Hulgan T; Raffanti SP; Koethe JR; Sterling TR
Clin Infect Dis; 2020 Mar; 70(7):1267-1274. PubMed ID: 31100116
[TBL] [Abstract][Full Text] [Related]
9. Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors or non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: A multicenter retrospective cohort study.
Lagi F; Baldin G; Colafigli M; Capetti A; Madeddu G; Kiros ST; Di Giambenedetto S; Sterrantino G
Int J Antimicrob Agents; 2019 Oct; 54(4):487-490. PubMed ID: 31195121
[TBL] [Abstract][Full Text] [Related]
10. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research.
Dorward J; Lessells R; Drain PK; Naidoo K; de Oliveira T; Pillay Y; Abdool Karim SS; Garrett N
Lancet HIV; 2018 Jul; 5(7):e400-e404. PubMed ID: 29884404
[TBL] [Abstract][Full Text] [Related]
11. Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study.
Phillips AN; Venter F; Havlir D; Pozniak A; Kuritzkes D; Wensing A; Lundgren JD; De Luca A; Pillay D; Mellors J; Cambiano V; Bansi-Matharu L; Nakagawa F; Kalua T; Jahn A; Apollo T; Mugurungi O; Clayden P; Gupta RK; Barnabas R; Revill P; Cohn J; Bertagnolio S; Calmy A
Lancet HIV; 2019 Feb; 6(2):e116-e127. PubMed ID: 30503325
[TBL] [Abstract][Full Text] [Related]
12. Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy.
Chen GJ; Sun HY; Chang SY; Cheng A; Huang YS; Huang SH; Huang YC; Su YC; Liu WC; Hung CC
Int J Infect Dis; 2021 Apr; 105():147-151. PubMed ID: 33592339
[TBL] [Abstract][Full Text] [Related]
13. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral therapy in older people with HIV.
Richterman A; Sax PE
Curr Opin HIV AIDS; 2020 Mar; 15(2):118-125. PubMed ID: 31990705
[TBL] [Abstract][Full Text] [Related]
15. Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment.
Bade AN; McMillan JM; Liu Y; Edagwa BJ; Gendelman HE
Mol Neurobiol; 2021 Nov; 58(11):5703-5721. PubMed ID: 34390469
[TBL] [Abstract][Full Text] [Related]
16. Dolutegravir with boosted darunavir as treatment simplification for treatment-experienced HIV patients with multiple mutations.
Paparizos V; Vasalou V; Kourkounti S
Int J STD AIDS; 2019 Oct; 30(12):1214-1215. PubMed ID: 31775586
[No Abstract] [Full Text] [Related]
17. Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility.
Fabbiani M; Grima P; Milanini B; Mondi A; Baldonero E; Ciccarelli N; Cauda R; Silveri MC; De Luca A; Di Giambenedetto S
Antivir Ther; 2015; 20(4):441-7. PubMed ID: 25516553
[TBL] [Abstract][Full Text] [Related]
18. HIV 101: fundamentals of antiretroviral therapy.
Saag MS
Top Antivir Med; 2019 Sep; 27(3):123-127. PubMed ID: 31634859
[TBL] [Abstract][Full Text] [Related]
19. Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV.
Nichols SL; Bethel J; Kapogiannis BG; Li T; Woods SP; Patton ED; Ren W; Thornton SE; Major-Wilson HO; Puga AM; Sleasman JW; Rudy BJ; Wilson CM; Garvie PA;
J Neurovirol; 2016 Apr; 22(2):218-30. PubMed ID: 26463526
[TBL] [Abstract][Full Text] [Related]
20. Machine learning models reveal neurocognitive impairment type and prevalence are associated with distinct variables in HIV/AIDS.
Tu W; Chen PA; Koenig N; Gomez D; Fujiwara E; Gill MJ; Kong L; Power C
J Neurovirol; 2020 Feb; 26(1):41-51. PubMed ID: 31520320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
